

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/515,363	02/29/2000	Paul B. Fisher	A34614/070050.1690	1657
7590 12/18/2003			EXAMINER	
Lisa B. Kole BAKER & BOTTS			QIAN, CELINE X	
30 Rockefeller Plaza New York, NY 10112			ART UNIT	PAPER NUMBER
			1636	

DATE MAILED: 12/18/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Office Action Occurrence	09/515,363	FISHER ET AL.				
Office Action Summary	Examiner	Art Unit				
	Celine X Qian	1636				
The MAILING DATE of this communication app Period for Reply	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status						
1) Responsive to communication(s) filed on <u>23 September 2003</u> .						
2a) ☐ This action is <b>FINAL</b> . 2b) ☑ This	action is non-final.					
3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>1,2 and 4-11</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5)⊠ Claim(s) <u>1</u> is/are allowed.						
6)⊠ Claim(s) <u>2 and 4-11</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or	r election requirement.					
Application Papers						
9) The specification is objected to by the Examine						
10) $\boxtimes$ The drawing(s) filed on <u>27 August 2002</u> is/are: a) $\boxtimes$ accepted or b) $\square$ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. §§ 119 and 120						
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> <li>13) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet.</li> <li>37 CFR 1.78.</li> <li>a) The translation of the foreign language provisional application has been received.</li> <li>14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.</li> </ul>						
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) 🔲 Interview Summary (	PTO-413) Paper No(s)				
Notice of Draftsperson's Patent Drawing Review (PTO-948)     Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal Pa	atent Application (PTO-152)				

Application/Control Number: 09/515,363

Art Unit: 1636

#### **DETAILED ACTION**

Claims 1, 2 and 4-11 are pending in the application.

This Office Action is in response to the Amendment filed on 9/26/03.

#### Response to Amendment

The rejection of claim 4 under 35 U.S.C.102 (a) has been withdrawn in light of Applicant's amendment of the claim.

The rejection of claims 5-11 under 35 U.S.C.103 (a) has been withdrawn in light of Applicant's amendment of the claims.

Claims 2 and 4-11 are rejected under 35 U.S.C.112 1<sup>st</sup> paragraph for reasons discussed below.

### New Grounds of Rejection

## Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 2 and 4-11 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The written description requirement is set forth by 35 U.S.C. 112, first paragraph which states that the: "specification shall contain a written description of the invention. . . [emphasis

Application/Control Number: 09/515,363

Art Unit: 1636

added]." The written description requirement has been well established and characterized in the case law. A specification must convey to one of skill in the art that "as of the filing date sought, [the inventor] was in possession of the invention." See *Vas Cath v. Mahurkar* 935 F.2d 1555, 1560 19 USPQ2d 1111, 1117 (Fed. Cir. 1991). Applicant may show that he is in "possession" of the invention claimed by describing the invention with all of its claimed limitations "by such descriptive means as words, structures, figures, diagrams, formulas, etc., that fully set forth the claimed invention." See *Lockwood v. American Airlines Inc.* 107 F.3d 1565, 1572, 41 USPQ2d 1961, 1966 (Fed. Cir. 1997).

In analyzing whether the written description requirement is met, it is first determined whether a representative number of species have been described by their complete structure.

Next, it is determined whether a representative number of species have been sufficiently described by other relevant identifying characteristics. Claim 2 is drawn to a nucleic acid encoding an Mda-5 polypeptide. This claim encompasses both cDNA and genomic DNA that encoding Mda-5 protein. However, the specification only teaches cDNA sequence that encodes Mda-5 but not the genomic sequence. The genomic sequence including exons and introns cannot be deduced from the polypeptide sequence SEQ ID NO:2. As such, the specification fails to describe the claimed invention by their complete structure or other identifying characteristics.

Claim 4 encompasses a large genus of nucleic acids of various sizes that hybridize to DNA of SEQ ID NO:1 or its complementary strand. Such nucleic acid ranges from oligonucleotide to potentially unlimited size of DNA depending on the stringency of the hybridizing condition. Although claim 4 recites said nucleic acid encodes a polypeptide having growth suppressive activity, other than the full size Mda-5 and one deletion mutant, the

Application/Control Number: 09/515,363

Art Unit: 1636

Page 4

specification fails to describe any nucleic acids that are hybridizable to SEQ ID NO:1 and have

this function. It is unclear what structural requirement, for example the functional domain, is

necessary for growth suppressive activity. Therefore, the specification fails to describe a

representative number of species of the invention by their complete structure or other identifying

characteristics. As such, the written description requirement is not met.

Conclusion

Claim 1 is allowed.

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Celine X Qian whose telephone number is 703-306-0283. The

examiner can normally be reached on 9:00-5:30 M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Remy Yucel Ph.D. can be reached on 703-305-1998. The fax phone number for the

organization where this application or proceeding is assigned is 703-305-3014.

Any inquiry of a general nature or relating to the status of this application or proceeding

should be directed to the receptionist whose telephone number is 703-308-0196.

Celine Qian, Ph.D.

ANNE-MARIE FALK, PH.I.

Anne-marie Talk